Aesthetic Medical International Holdings Group Ltd financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Aesthetic Medical International Holdings Group Ltd files with the SEC in its annual reports.

In CNY millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	697	761	869	902	646	670	683	756
Cost of revenue	235	259	276	357	376	315	361	418
Gross profit	463	503	593	545	270	356	322	338
Selling and marketing	300	334	413	511	405	226	232	241
Interest expense	6.58	9.24	24.3	29.2	27.2	21.6	14.5	8.72
Interest income	0.87	0.32	0.39	1.19	0.11	0.16	0.08	0.4
Pre-tax income	-53.2	-234	152	-259	-681	-94.2	-55.1	-1.35
Income tax	19.3	18.5	14	-12.6	-11.8	-18.1	-15.1	23.7
Net income to minority interests	4.25	2.76	2.02	-11.4	-82.9	0.14	-2.49	-5.13
Net income	-76.7	-255	136	-235	-587	-76.2	-37.4	-19.9
EPS, basic	-1.87	-6.22	2.96	-3.61	-8.89	-0.93	-0.28	-0.14
EPS, diluted	-1.87	-6.22	-0.78	-3.61	-8.89	-0.93	-0.28	-0.14

Balance sheet

	FY2017	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Cash and equivalents	105	102	154	44.4	39.3	12.2	62.3	42.8
Receivables						25.9	21.7	18.4
Inventory		21.1	26.1	33.3	30.6	27.9	15.6	14.9
Total current assets		283	265	206
Property, plant and equipment	210	235	519	532	359	321
Total assets		677	1,047	1,038	577	546	561	486
Total current liabilities		171	265	302	542	544	411	402
Lease liabilities			166	179	106	99.3	84.2	61.1
Total liabilities		926	457	612	763	672	527	477
Total debt		97	140	212	234	202	105	85.9
Retained earnings		-374	-242	-478	-1,065	-1,141	-1,178	-1,198
Shareholders' equity		-278	547	391	-157	-114	48.9	30.5
Minority interests		29.1	43.1	34.8	-29.8	-12.2	-15.3	-21.1
Total equity	-22.2	-249	591	426	-186	-126	33.6	9.35
Total liabilities and equity		677	1,047	1,038	577	546	561	486

Cash flow statement

	FY2017	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Net income	-72.4	-252	138	-247	-670	-76.1	-39.9	-25.1
Depreciation and amortization	29.1	32.1	83.8	106	99.1	61.5	65.9	66
Cash from operations	77	4.89	86.8	-0.84	51.1	-75.1	74.3	79.7
Capital expenditures	-47.5	-45.5	-69.1	-38.4	-33.2	-1.6	-55.2	-30.6
Cash from investing	-69.2	-76.2	-114	-127	-11.5	3.11	-52.2	-30.3
Debt issued	46	109	140	277	97.9	164	85.2	67
Debt repaid	-65.2	-57.9	-104	-218	-68.9	-142	-130	-63
Share buybacks				-1.98				-2.02
Cash from financing	-28.2	66.7	79.6	17.7	-45.2	45.6	29.1	-68.6
Exchange rate effect	-3.22	1.09	0.45	0.41	0.57	-0.67	-0.93	-0.3
Free cash flow	29.5	-40.6	17.6	-39.2	17.9	-76.7	19	49.1
Income taxes paid	-20.8	-25	-13.9	-6.43	-0.62	0.63	0.02	0.52

Key metrics

Worked out from the statements above. Latest values use fiscal 2024. No valuation: the share price is quoted in a different currency than the statements.

Profitability

Metric	Value	How it is calculated
Gross margin	44.7%	Gross profit / revenue.
Pre-tax margin	-0.2%	Pre-tax income / revenue.
Net margin	-2.6%	Net income / revenue.
FCF margin	6.5%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	10.5%	Cash from operations / revenue.
Return on equity (ROE)	-50.3%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-3.8%	Net income / average total assets.
Capex / revenue	4.0%	Capital expenditures / revenue.
D&A / revenue	8.7%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	10.7%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	5.4%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-2.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	4.9%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	7.8%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-10.6%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	7.2%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	16.0%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-1.7%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	157.7%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	40.1%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	22.7%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-37.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y	-43.9%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-13.3%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-5.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-14.2%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.

Balance sheet health

Metric	Value	How it is calculated
Quick ratio	0.15x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.11x	(Cash + short-term investments) / current liabilities.
Debt / equity	2.82x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	17.7%	Total debt / total assets.
Liabilities / assets	98.1%	Total liabilities / total assets.
Net debt	CN¥43.1M	Total debt - cash - short-term investments. Negative means more cash than debt.
Tangible book value	CN¥30.5M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.44x	Revenue / average total assets.
Inventory turnover	27.4x	Cost of revenue / average inventory.
Days inventory	13 days	365 x average inventory / cost of revenue.
Receivables turnover	37.8x	Revenue / average receivables.
Days sales outstanding	10 days	365 x average receivables / revenue.
Capex / operating cash flow	38.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-CN¥0.14	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic	-CN¥0.14	Net income per basic share, as reported (split-adjusted).
Buybacks / FCF	4.1%	Share buybacks / free cash flow, when free cash flow is positive.

What was Aesthetic Medical International Holdings Group Ltd's revenue in fiscal 2024?

Aesthetic Medical International Holdings Group Ltd reported revenue of CN¥755.7M for fiscal 2024, 10.7% higher than the year before.

Was Aesthetic Medical International Holdings Group Ltd profitable in fiscal 2024?

No. It reported a net loss of CN¥19.9M.

How much free cash flow did Aesthetic Medical International Holdings Group Ltd generate in fiscal 2024?

Cash from operations of CN¥79.7M minus capital expenditures of CN¥30.6M left free cash flow of CN¥49.1M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Aesthetic Medical International Holdings Group Ltd